ClinicalTrials.gg
RecruitingNCT07216534Updated Oct 16, 2026

Virtual Reality Viewing of Unaltered Streetscape Versus Digitally Manipulated Opposite Streetscape to Assess Psychosocial Response in Participants

An interventional study of Survey Administration and Virtual Technology Intervention in Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm and Psychiatric Disorder, sponsored by Ohio State University Comprehensive Cancer Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Ohio State University Comprehensive Cancer Center · Not applicable, Interventional, and Prevention

How we know

Updated Oct 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical trial compares virtual reality viewing of an unaltered streetscape versus a digitally manipulated opposite streetscape to assess the psychosocial response in participants. Visible measures of neighborhood factors might be associated with health outcomes and risk factors of those outcomes. Short-term exposure to virtual reality environments representing very high or very low levels of neighborhood physical disorder - presence or absence of garbage/litter, presence or absence of graffiti, presence or absence of an abandoned building, presence or absence of large dumpsters, poor or very well-kept building conditions, poor or very well-kept yard conditions, poor or very well-kept road verge conditions may be a safe and effective way to assess psychosocial response in participants.

Read the detailed description

PRIMARY OBJECTIVES:

I. Compare sympathetic autonomic measures (heart rate variability and skin conductance) between participants viewing, in virtual reality, their streetscape as a digitally manipulated opposite version with respect to physical disorder indicators versus participants viewing their streetscape as a digital twin with respect to physical disorder indicators.

II. Compare self-report measures (Self-Assessment Manikin and state anxiety ratings) between participants viewing, in virtual reality, their streetscape as a digitally manipulated opposite version with respect to physical disorder indicators versus participants viewing their streetscape as a digital twin with respect to physical disorder indicators.

III. Record side effects of interacting within a virtual reality environment over short periods of time (3-5 min):

IIIa. Quantify frequency of side effects; IIIb. Explore whether side effects increase across subsequent VR sessions of the cross-over study; IIIc. Explore whether side effects vary by VR intervention arm (digital twin of own streetscape or digitally manipulated opposite indicators of physical disorder of own streetscape).

IV. Analyze impact of covariates on study outcomes.

EXPLORATORY OBJECTIVES:

I. Compare eye gaze density between participants viewing, in virtual reality, their streetscape as a digitally manipulated opposite version with respect to physical disorder indicators versus participants viewing their streetscape as a digital twin with respect to physical disorder indicators.

II. Compare self-report measures (neighborhood social cohesion and neighborhood disorder) between participants viewing, in virtual reality, their streetscape as a digitally manipulated opposite version with respect to physical disorder indicators versus participants viewing their streetscape as a digital twin with respect to physical disorder indicators.

OUTLINE: Participants are randomized within their residing neighborhood to 1 of 2 arms.

ARM I: Participants have their streetscape photographed. Participants view a standard residential streetscape using virtual reality (VR) for up to 5 minutes. Patients then view a digital twin of their streetscape with identical physical disorder using VR for up to 5 minutes followed by viewing their streetscape with the opposite physical disorder using VR for up to 5 minutes.

ARM II: Participants have their streetscape photographed. Participants view a standard residential streetscape using VR for up to 5 minutes. Patients then view their streetscape with the opposite physical disorder using VR for up to 5 minutes followed by viewing a digital twin of their streetscape with identical physical disorder using VR for up to 5 minutes.

02

Conditions studied

  • Hematopoietic and Lymphatic System Neoplasm
  • Malignant Solid Neoplasm
  • Psychiatric Disorder

Browse trials for

03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 32 is below the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Ohio State University Comprehensive Cancer Center is the lead sponsor of 376 studies on the registry; 82 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 19 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18+
  • Must currently live (4+ night/week) at the residence being studied. Only one resident per household will be selected
  • Must understand and be able to read English
  • Must agree to have residence photographed
  • Must be able to wear a VR head mounted display
  • Must live in neighborhood that has been selected for study
  • Must be willing and able to attend an approximately 2 hour in-person visit on Ohio State University (OSU) campus

Exclusion criteria

Exclusion Criteria:

  • Pregnant women
  • Visual or mobility impairment
  • Cannot have epilepsy or other condition that would inhibit them from being able to use a VR headset
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Arm I (twin followed by opposite streetscape)

    Participants have their streetscape photographed. Participants view a standard residential streetscape using VR for up to 5 minutes. Patients then view a digital twin of their streetscape with identical physical disorder using VR for up to 5 minutes followed by viewing their streetscape with the opposite physical disorder using VR for up to 5 minutes.

    Other: Survey Administration · Other: Virtual Technology Intervention

  • Experimental
    Arm II (opposite followed by twin streetscape)

    Participants have their streetscape photographed. Participants view a standard residential streetscape using VR for up to 5 minutes. Patients then view their streetscape with the opposite physical disorder using VR for up to 5 minutes followed by viewing a digital twin of their streetscape with identical physical disorder using VR for up to 5 minutes.

    Other: Survey Administration · Other: Virtual Technology Intervention

Interventions

  • OtherSurvey Administration

    Ancillary studies

  • OtherVirtual Technology Intervention

    View standard streetscape

    Also known as: Virtual Reality Intervention, Virtual Technology

  • OtherVirtual Technology Intervention

    View digital twin of streetscape

    Also known as: Virtual Reality Intervention, Virtual Technology

  • OtherVirtual Technology Intervention

    View opposite digital streetscape

    Also known as: Virtual Reality Intervention, Virtual Technology

06

What researchers measure

Primary outcomes

  1. Change in heart rate variability

    Mean heart rate variability over the entire session of each VR condition will be calculated from electrocardiograph data. Will compare the difference between two VR conditions (viewing opposite neighborhood image versus viewing twin neighborhood image) using a crossover design. Analyses of outcomes will be conducted using generalized linear mixed model approaches.

    Time frame: From baseline to completion of virtual reality (VR) viewings, up to 1 day

  2. Change in skin conductance

    Skin conductance, measured as microsiemens, will be calculated as the mean value over each VR condition. Will compare the difference between two VR conditions (viewing opposite neighborhood image versus viewing twin neighborhood image) using a crossover design. Analyses of outcomes will be conducted using generalized linear mixed model approaches.

    Time frame: From baseline to completion of VR viewings, up to 1 day

  3. Affective reaction

    Assessed via Self-assessment Manikin. Will compare the difference between two VR conditions (viewing opposite neighborhood image versus viewing twin neighborhood image) using a crossover design. Analyses of outcomes will be conducted using generalized linear mixed model approaches.

    Time frame: After completion of VR viewings, up to 1 day

  4. Anxiety

    Assessed via Spielberger State-Trait Anxiety Inventory short form. Will compare the difference between two VR conditions (viewing opposite neighborhood image versus viewing twin neighborhood image) using a crossover design. Analyses of outcomes will be conducted using generalized linear mixed model approaches.

    Time frame: After completion of VR viewings, up to 1 day

  5. Participant reported discomfort

    This is an open-ended outcome measure. Discomfort reported by participants will be recorded by study staff.

    Time frame: After completion of VR viewings, up to 1 day

07

Study locations

1 of 1 sites recruiting
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Jesse Plascak, PhD, MPH · Contact614-293-8024
    • Jesse Plascak, PhD, MPH · Principal investigator
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 12 months is below that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: start Sep 2026 → Jan 2027, primary completion Dec 2026 → Jan 2028 and completion Dec 2026 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2025
First posted
Oct 14, 2025
StartEst.
Jan 15, 2027was Sep 2026
Primary completionEst.
Jan 31, 2028was Dec 2026
CompletionEst.
Jan 31, 2028was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Jan 15, 2027
Oct 16, 2026
Primary completion
Dec 31, 2026→Jan 31, 2028
Oct 16, 2026
Study completion
Dec 31, 2026→Jan 31, 2028
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Sep 1, 2026→Jan 15, 2027
    Primary completion Dec 31, 2026→Jan 31, 2028
    Study completion Dec 31, 2026→Jan 31, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07216534
Responsible party
Jesse Plascak (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Oct 14, 2025
Start date
Jan 15, 2027 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Jesse Plascak, PhD, MPH
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion